Диссертация (1335925), страница 24
Текст из файла (страница 24)
Conti, F. Early occurrence and recurrence of hepatocellular carcinoma in HCV-relatedcirrhosis treated with direct-acting antivirals / F. Conti, F. Buonfiglioli, A. Scuteri [et al.] // JournalHepatology. – 2016. – Vol. 65, № 4. – Р. 727–733.145. Costantino, А. Naturally occurring mutations associated with resistance to HCV NS5Bpolymerase and NS3 protease inhibitors in treatmentnaïve patients with chronic hepatitis C /A. Costantino, E. Spada, M. Equestre [et at.] // Virology Journal.
– 2015. – № 12. – С. 186.146. Cross, T. The impact of hepatic steatosis on the natural history of chronic hepatitis Cinfection / Т. Cross, А. Quaglia, S. Hughes [et at.] // Journal Viral Hepatitis. – 2009. – № 16. – Р. 492–499.147. Crum-Cianflone, N. Nonalcoholic fatty liver disease among HIV-infected persons / N.Crum-Cianflone, A. Dilay, G. Collins // JAIDS. – 2009. – Vol. 50. – № 5. – P. 464–473.148. Csete, J. «Viral Time Bomb»: Health and Human Rights Challenges in AddressingHepatitis С in Canada [Электронный ресурс] / J. Csete, R.
Elliott, B. Fischer // Toronto: CanadianHIV/AIDS Legal Network, Centre for Addictions Research of ВС and Centre for Applied Research inMental Health and Addiction. – 2008. – 22 Р. – URL: http://www.aidslaw.ca/site/wp-content/uploads/2013/11/ViralTime Bomb-ENG.pdf.128149. Daniels, G. L. Human Blood Groups / G. L. Daniels. – 2-nd ed.
– Oxford : BlakwellScience, 2002. – 560 р.150. Deltenre, P. Studies on the epidemiology of hepatitis B and C virus infections are stillneeded / P. Deltenre // Journal Hepatology. – 2015. – № 62. – P. 1225–1227.151. Desmond, C. P. Sustained virological response rates and durability of the response tointerferon-based therapies in hepatitis C patients treated in the clinical setting / С.
Desmond,S. Roberts, F. Dudley // Journal Viral Hepatitis. – 2006. – Vol. 13. – P. 311–315.152. Di Bisceglie, A. Early virologic response after peginterferon alpha-2a plus ribavirin orpeginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C / А. Di Bisceglie,R. Ghalib, F. Hamzeh [et at.] // Journal Viral Hepatitis.
– 2007. – Vol. 14. – Р. 721–729.153. Dougla, M. Molecular mechanisms of insulin resistance in chronic hepatitis C /М. Douglas, J. George // World J. Gastroenterolgy. – 2009. – Vol. 35, № 15. – Р. 4356–4364.154. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // Journal ofHepatology.
– 2011. – Vol. 55. – Р. 245–264.155. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // Journal ofHepatology. – 2014. – Vol. 60. – Р. 392–420.156. EASL Recommendations on Treatment of Hepatitis C 2014 // Journal of Hepatology. –2014. – Vol. 60. – Р 392–420.157. EASL Recommendations on Treatment of Hepatitis C 2015 // Journal of Hepatology. –2015. – Vol.
63. – P. 199–236.158. EASL Recommendations on Treatment of Hepatitis C 2016 // Journal of Hepatology. –2016. Sep 12 [pii: S0168-8278(16)30489-5. doi:10.1016/j.jhep.2016.09.001].159. EASL Recommendations on Treatment of Hepatitis C 2017 // Journal of Hepatology. –2017. – Vol. 66. – P. 153–194.160. Electronic resource. – URL: http://rospotrebnadzor.ru/ (in Russian).161. Eslam, М. Interferon-χ rs12979860 genotype and liverfibrosis in viral and non-viral chronicliver disease/ М.
Eslam, R. Leung, M. Romero-Gomez // Naturecommunication. – 2015. – № 6. – P.6422 [doi:10.1038/ncomms7422/www.nature.com/naturecommunications], 2015.162. Esteban, R. Successful retreatment with sofosbuvir-containing regimens for HCV genotype2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy / R. Esteban, L. Nyberg,J. Lalezari [et al.] // Journal of Hepatology. – 2014. – № 60. – Р.
S4–S5.163. Eurich, D. Transforming growth factor beta1 polymorphisms and progression of graftfibrosis after liver transplantation for hepatitis C virus-induced liver disease / D. Eurich, M. Bahra,S. Boas-Knoop [et al.] // Liver Transplantation. – 2011. – Vol. 17.
– P. 279–288.164. European Association for the Study of the Liver. EASL Clinical Practice Guidelines:129management of hepatitis С virus infection // Journal of Hepatology. – 2011. – Vol. 55. – Р. 245–264.165. Everhart, J. Weight-related effects on disease progression in the hepatitis C antiviral longterm treatment against cirrhosis trial / J. Everhart, A. Lok, H. Kim [et al.] // Gastroenterology.
– 2009.– Vol. 137, № 2. – Р. 549–557.166. Fabris, С. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role inthe course of chronic viral hepatitis and the development of HCC / C. Fabris, T. Falleti, F. Cussigh [etal.] // Journal of Hepatology.
– 2011. – Vol. 54. – Р. 716–722.167. Fagherazzi, G. ABO and Rhesus blood groups and risk of type 2 diabetes: evidence fromthe large E3N cohort study / G. Fagherazzi, G. Gusto, F. Clavel-Chapelon [et al.] // JournalDiabetologia. – 2015. – Vol. 58. – P. 519–522.168. Fan, X. High diversity of associated with early virological respon therapy / X.
Fan, Q. Mao,D. Zhou [et al.] // Journal Hepatology. – 2009. – Vol. 50. – Р. 1765–1772.169. Fattovich, G. IL28B Polymorphisms, IP-10 and Viral Load Predict Virological Response toTherapy in Chronic Hepatitis C / G. Fattovich, L. Covolo, S. Bibert [et al.] // AlimentaryPharmacology & Therapeutics. – 2011. – Vol. 33, № 10.
– Р. 1062–1072.170. Feld, J. Mechanism of action of interferon and ribavirin in treatment of hepatitis С / J. Feld,J. Hoofnagle // Nature. – 2005. – Vol. 436. – Р. 967–972.171. Ferenci, P. Predicting sustained virological responses in chronic hepatitis C patients treatedwith peginterferon alfa-2a (40 KD)/ribavirin / Р. Ferenci, M. Fried, М.Shiffman [et al.] // JournalHepatology. – 2005. – Vol. 43. – Р.
425–433.172. Ferenci, Р. A tool to select patients with a high probability of sustained virological responseto peginterferon Alfa-2A (40 kDa)/ribavirin / P. Ferenci, R. Aires, L. Ancuta [et al.] // LiverInternational. – 2014. – Vol. 34. – Р. 1550–1559.173. Fonts, X. Simeprevir with peg-interferon and ribavirin leads to high rates of SVR in patientswith HCV genotype I who relapsed after previous therapy: a phase 3 trial / X.
Fonts, E. Lawitz,S. Zeuzem [et al.] // Gastroenterology. – 2014. – Vol. 146. – Р. 1669–1679.174. Foster, G. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patientsWith HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2infection / G. Foster, S. Pianko, A. Brown [et al.] // Gastroenterology. – 2015. – Vol. 149, № 6. –Р.
1462–1470.175. Fried, M. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection /M. Fried, M. ShifTman, K. Reddy [et al.] // New England Journal Medicine. – 2002. – Vol. 347, № 13.– Р. 975–982.176. Fried, M. Rapid virological response is the most important predictor of sustained virologicalresponse across genotypes in patients with chronic hepatitis С virus infection / M. Fried, S. Hadziyannis,130M. Shiffman [et al.] // Journal Hepatology. – 2011 – Vol. 55. – Р. 69–75.177. Friedman, S. Hepatic fibrosis 2006: report of the third AASLD Single Topic Conference /S.
Friedman // Journal Hepatology. – 2007. – № 45. – P. 242–249.178. Gara, N. What the infectious disease physician needs to know about pegylated interferonand ribavirin / N. Gara, M. Ghany // Journal Clinical Infectious Diseases. – 2013. – Vol. 56. –P. 1629–1636.179. Garratty, G. ABO and Rh (D) phenotype frequencies of different racial/ethnic groups in theUnited States / G. Garratty, S.
Glynn, R. McEntire // Transfusion. – 2004. – V. 44. – P. 703–706.180. PaWlovsci // Gastroenterology. – 2016 Jul. – № 151 (1). – P. 70–86 [doi: 10.1053/j. gastro.2016.04.003. Epub 2016 Apr 11. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs inInterferon-Free Regimens].181. Ge, D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance /D. Ge, J. Fellay, A. Thompson [et al.] // Nature. – 2009.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
